02.2023

We are very happy to see Ventac portfolio company Regenesance BV (dba Complement Pharma BV) publish a research article with Alexion, AstraZeneca Rare Disease in the J. of Innate Immunity. The paper describes the development and validation of a new humanized C6 monoclonal antibody that inhibits assembly of the membrane attack complex (MAC): a key part of the innate immune system. The antibody has potential to treat neuronal disease by preventing MAC formation and disease progression.

Research article: https://www.karger.com/Article/Pdf/524587